Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
IPO Year: 2011
Exchange: NASDAQ
Website: pacira.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2025 | $8.00 → $25.00 | Sell → Hold | Truist |
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/12/2024 | $37.00 → $14.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/3/2024 | $38.00 → $25.00 | Overweight → Equal Weight | Barclays |
| 3/7/2024 | $80.00 → $45.00 | Overweight | JP Morgan |
| 12/20/2023 | $42.00 | Outperform | Raymond James |
| 8/3/2023 | $50.00 | Market Perform → Outperform | TD Cowen |